TNF -857C>T: A Distinct Inflammatory Control Point
The TNF gene on chromosome 6p21.3 encodes tumor necrosis factor-alpha | a master cytokine controlling inflammation, immune cell activation, and apoptosis.
The rs1799724 variant sits 857 base pairs upstream of the TNF transcription start site, within the gene's
promoter — a regulatory region that controls how much TNF-alpha your immune cells produce. Unlike the
well-studied -308 variant (rs1800629), the -857C>T polymorphism works through a distinct molecular
mechanism and shows population-specific disease associations.
The Mechanism
The -857 position overlaps an OCT-1 binding site | a binding site for octamer transcription factor-1,
a protein that binds to DNA and regulates nearby gene expression.
The T allele disrupts this binding site, altering the transcriptional regulation of TNF-alpha independently
of the NF-κB binding site affected by the -308 variant. Because these two promoter polymorphisms operate
via distinct transcription factor binding sites, they can produce additive or independent effects on
TNF expression. The TNF gene is on the forward (plus) strand, so the C>T notation in papers corresponds
directly to plus-strand alleles as reported in genome files.
The Evidence
The clearest disease association for the -857 T allele is in Asian populations with
Crohn's disease | a chronic inflammatory bowel disease affecting the gastrointestinal tract.
A meta-analysis of 31 studies found that Asians carrying the T allele had a 54% increased risk of
Crohn's disease compared to CC carriers (OR 1.54, 95% CI 1.19–1.99). This ethnic specificity is
notable — studies in European and Middle Eastern populations have not consistently replicated
the IBD association, underscoring the importance of population context in interpreting this variant.
For psoriasis, a 2023 systematic review and meta-analysis | Sadafi et al., Heliyon
found robust associations across five genetic models: the T allele conferred OR 1.57 in allelic
comparison, and TT homozygotes showed OR 1.98 for psoriasis risk. This association was confirmed by
trial sequential analysis, suggesting sufficient evidence for a genuine effect. The -857 variant is
also among polymorphisms associated with psoriatic arthritis in a meta-analysis of 14 studies.
A clinically important finding concerns response to anti-TNF biologic drugs | medications like
infliximab, adalimumab, and etanercept that block TNF-alpha protein.
A meta-analysis found that the common C allele — not the risk T allele — is associated with better
response to TNF blockers (OR 1.78, 95% CI 1.13–2.80). Carriers of the T allele may therefore show
reduced efficacy from anti-TNF biologics in conditions like Crohn's disease and spondyloarthropathy.
A recent meta-analysis also links the T allele to increased type 1 diabetes susceptibility.
Practical Actions
For T allele carriers with active or suspected inflammatory bowel disease — particularly those of
East Asian ancestry — this variant provides one more reason to pursue thorough gastroenterological
evaluation. The -857 T allele adds biologically independent risk information beyond the more commonly
tested -308 variant.
For T allele carriers with psoriasis or psoriatic arthritis, awareness of this genetic background
may be relevant when discussing biologic therapy choices: if anti-TNF drugs are being considered,
the -857 T allele predicts a somewhat less favorable response compared to C allele carriers. Switching
to IL-17 or IL-23 inhibitors may be a better initial strategy.
Interactions
The -857 variant sits within a cluster of TNF promoter polymorphisms, including rs1800629 | TNF -308 G>A,
the most studied TNF promoter variant, rs1800630 | TNF -863 C>A,
and rs361525 | TNF -238 G>A. These SNPs are in partial
linkage disequilibrium and can travel together on haplotypes; however, because they affect distinct
transcription factor binding sites, each can contribute independent regulatory information. The
combined effect of multiple TNF promoter variants on biologic drug response has been studied in
Crohn's disease and psoriasis, and T allele carriers at -857 may compound the reduced anti-TNF
response seen with A allele carriers at -308.
All Genotypes
Common genotype with standard TNF promoter function
You have two copies of the common C allele at the TNF -857 position. This genotype preserves normal OCT-1 binding at the TNF promoter and is associated with standard TNF-alpha regulation. About 82% of people carry this genotype globally, though frequencies vary by ancestry. If you have autoimmune disease requiring biologic therapy, CC carriers tend to respond better to anti-TNF drugs than T allele carriers.
One copy of the T allele — moderately elevated TNF regulatory risk
You carry one copy of the T allele, which disrupts an OCT-1 binding site in the TNF promoter. About 17% of people share this heterozygous genotype globally. Your risk profile sits between CC and TT carriers. The T allele is associated with increased risk of psoriasis, psoriatic arthritis, and Crohn's disease susceptibility in Asian populations. If anti-TNF biologics are prescribed for an inflammatory condition, your response may be somewhat reduced compared to CC homozygotes.
Two copies of the T allele — highest TNF -857 inflammatory risk
You have two copies of the T allele, the rarest genotype at this position (approximately 1% of people globally, higher in East Asian populations where T allele frequency reaches ~13%). TT homozygotes show the strongest association with psoriasis risk (OR ~1.98 compared to CC) and carry the greatest TNF -857-related susceptibility to inflammatory conditions. If you are of East Asian descent, this genotype also confers meaningfully elevated Crohn's disease risk. Anti-TNF biologics are predicted to be less effective in TT carriers than in CT or CC carriers.